Risk Factors for Thrombocytopenia in Adult Chinese Patients Receiving Linezolid Therapy

Chen, Chao; Guo, Dai-Hong; Cao, Xiutang; Cai, Yun; Xu, Yuanjie; Zhu, Ming; Ma, Liang

doi:10.1016/j.curtheres.2012.07.002

Cited by 54 publications

(68 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many retrospective studies have described various risk factors for linezolid-induced thrombocytopenia, with the main potential risk factors including renal impairment, [4][5][6][7][8][9][10][11] prolonged treatment duration, 4,5,10) hypoalbuminemia, 10) and lower body weight. 10,11) Hyponatremia was observed in 7% of patients treated with linezolid in a phase III clinical trial in Japan. 12) Hyponatremia is the most common impairment of body fluid and electrolyte balance encountered in the clinical setting.…”

mentioning

confidence: 99%

A Retrospective Analysis of Risk Factors for Linezolid-Associated Hyponatremia in Japanese Patients

Tanaka

Suzuki

Takumi

et al. 2016

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Linezolid is an oxazolidinone antibiotic against Gram-positive bacteria. Although thrombocytopenia is a major adverse effect of linezolid, hyponatremia also often develops after linezolid administration. This study examined the frequency of hyponatremia that developed during linezolid treatment and identified its risk factors. In this retrospective, single-center, observational cohort study, 61 hospitalized patients treated with linezolid between January 2013 and January 2015 were analyzed. Hyponatremia was defined as a sodium level of ≤134 mEq/L for the duration of linezolid treatment. Its risk factors were identified via a logistic regression analysis. Hyponatremia occurred in 11 (18.0%) patients, and it was severe in a case (a sodium level of ≤128 mEq/L). Univariate and multiple logistic regression analyses identified the plasma C-reactive protein (CRP) level before the initial administration of linezolid and the concomitant use of a potassium-sparing diuretic as the independent variables associated with the development of hyponatremia. The odds ratios were 1.081 (95% confidence interval [CI]; 1.008-1.158) (p 0.028) and 11.017 (95% CI; 1.869-64.939) (p 0.008), respectively. Before linezolid treatment, the CRP levels of the hyponatremia group were significantly higher than those of the no-hyponatremia group (p<0.001). The frequency of hyponatremia development was significantly higher in the patients who received both the potassium-sparing diuretic and linezolid ( p 0.016). These results suggest that the plasma sodium levels of patients with severe inflammation who are treated with linezolid and those of linezolid-treated patients co-administered a potassium-sparing diuretic should be continuously monitored.

show abstract

mentioning

confidence: 99%

A Retrospective Analysis of Risk Factors for Linezolid-Associated Hyponatremia in Japanese Patients

Tanaka

Suzuki

Takumi

et al. 2016

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

show abstract

“…We thought that usage of these drugs also affected the development of thrombocytopenia in our second patient. Due to this, we advise that more attention should be paid to the development of thrombocytopenia when LZD is used with other anti-infective medications as in our second case 13 .…”

Section: Discussionmentioning

confidence: 99%

“…We believed that this factor also affected the development of thrombocytopenia in our patients. The concomitant use of meropenem with LZD and use of vancomycin prior to LZD may worsen thrombocytopenia 12,13 . Vancomycin was given to our second patient prior to LZD and meropenem was given concomitantly.…”

Section: Discussionmentioning

confidence: 99%

Böbrek fonksiyon bozukluğu olan iki hastada linezolide bağlı trombositopeni

Melek

Atmış

Bayazıt

et al. 2016

Cukurova Medical Journal (Çukurova Üniversitesi Tıp Fakültesi Dergisi)

View full text Add to dashboard Cite

AbstractÖz Linezolid is an oxazolidinone antibiotic, active against gram-positive bacteria that are resistant to other antibiotics including glycopeptides. Thrombocytopenia is an adverse effect of linezolid. Although various risk factors have been suggested, the mechanisms behind this side effect are largely unknown. Here, we report two adolescents with the diagnosis of chronic kidney disease who developed thrombocytopenia following treatment with linezolid. Our purpose in highlighting these cases is to increase the clinical awareness concerning this side effect of linezolid. While it is well known that thrombocytopenia may develop during linezolid treatment, it is relatively unknown that patients with renal dysfunction have an increased risk for the development of thrombocytopenia compared to patients without renal dysfunction.Linezolid, glikopeptidlerde dahil diğer antibiyotiklere dirençli gram pozitif bakterilere karşı etkin olan oksazolidinon grubu bir antibiyotiktir. Linezolid kullanımına bağlı görülen yan etkilerden birisi trombositopenidir. Trombositopeniye neden olan farklı birçok risk faktörü bildirilmesine karşın, bu yan etkinin nedeni tam olarak bilinmemektedir. Burada kliniğimizde kronik böbrek hastalığı tanısı ile izlenen ve linezolid tedavisi sırasında trombositopeni gelişen iki vakayı sunduk. Bu vakaları sunmaktaki amacımız linezolidin bu yan etkisi hakkında farkındalığı artırmaktır. Çünkü, linezolid tedavisi sırasında trombositopeni görülebileceği çok iyi bilinmesine karşın, bu yan etkinin gelişme riskinin böbrek fonksiyon bozukluğu olanlarda olmayanlara göre daha yüksek olduğu bilinmemektedir.

show abstract

“…10 Thrombocytopenia is a common adverse effect in adult patients and the incidence of linezolidrelated thrombocytopenia has been reported about 15-50%. 7,11,12 The other common drugrelated side effects reported with linezolid therapy were diarrhea, nausea, headache, neuropathy, and abnormal liver function tests. 13 These adverse effects were mostly detected in patients receiving linezolid for longer than 2 weeks.…”

Section: Discussionmentioning

confidence: 99%

Linezolid-related adverse effects in clinical practice in children

et al. 2017

View full text Add to dashboard Cite

Introduction:Linezolid may cause adverse effects such as thrombocytopenia, which were found to be dependent on receiving linezolid for longer than 2 weeks. There are limited studies concerning the safety and timing of linezolidrelated adverse effects in children. Objective of this study was to evaluate the incidence of adverse effects associated with linezolid, with especially focusing on the time of occurrence. Population and Methods: All children (≤18 years of age) who received ≥3 days of linezolid therapy were included in this study. Adverse effects attributed to linezolid and time of occurrence of side effects was evaluated.

show abstract

Risk Factors for Thrombocytopenia in Adult Chinese Patients Receiving Linezolid Therapy

Cited by 54 publications

References 23 publications

A Retrospective Analysis of Risk Factors for Linezolid-Associated Hyponatremia in Japanese Patients

A Retrospective Analysis of Risk Factors for Linezolid-Associated Hyponatremia in Japanese Patients

Böbrek fonksiyon bozukluğu olan iki hastada linezolide bağlı trombositopeni

Linezolid-related adverse effects in clinical practice in children

Contact Info

Product

Resources

About